Colossal Biosciences

Colossal Biosciences remained a private company as of the research date, with no confirmed IPO date, timeline, or public listing plans identified from company statements, press releases, or reliable news sources. The company, led by Co-Founder and CEO Ben Lamm, continued to focus on raising private capital and expanding its de-extinction and genetic engineering business rather than announcing any public offering.In January 2025, Colossal closed a $200 million Series C financing round led by TWG Global, which valued the company at $10.2 billion (https://www.businesswire.com/news/home/20250115365884/en/Colossal-Secures-$200M-in-Series-C-Funding-From-TWG-Global-on-the-Back-of-Numerous-Worlds-First-Scientific-Breakthroughs-on-Path-to-De-Extinction). This valuation reflected strong investor interest following the company's widely publicized de-extinction milestones, including the birth of dire wolf pups, but no subsequent public statement tied this funding to a future IPO timeline.No further updates on IPO preparation, underwriters, target exchange, or expected pricing were found in verifiable sources, so a specific forecast window could not be established.